(NASDAQ: CSTL) Castle Biosciences's forecast annual revenue growth rate of -5.96% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.85%.
Castle Biosciences's revenue in 2025 is $347,083,000.On average, 1 Wall Street analysts forecast CSTL's revenue for 2025 to be $8,541,296,946, with the lowest CSTL revenue forecast at $8,541,296,946, and the highest CSTL revenue forecast at $8,541,296,946. On average, 1 Wall Street analysts forecast CSTL's revenue for 2026 to be $8,635,998,140, with the lowest CSTL revenue forecast at $8,635,998,140, and the highest CSTL revenue forecast at $8,635,998,140.
In 2027, CSTL is forecast to generate $9,410,642,351 in revenue, with the lowest revenue forecast at $9,410,642,351 and the highest revenue forecast at $9,410,642,351.